Diabetes prevention spurs development programs
Researchers at a group of big drug companies, including GSK, Takeda and Novartis, have begun to study whether drugs currently prescribed to treat diabetes can be used to prevent the disease. The winners in this field can potentially open up a huge new market for drugs that already offer a good safety profile. Amylin and Eli Lilly are both active here as well. Some analysts peg the market for diabetes-prevention at $15 billion. Some 54 million Americans are considered pre-diabetic.
- read The Wall Street Journal report on diabetes therapies (sub. req.)
Be the first to comment
More stories about pharmaceuticals Eli Lilly GlaxoSmithKline safety profile analysts Novartis Takeda
Comments
By Anonymous | Posted 9:17am | October 16, 2006
Merck always seems to be a forerunner. Does anybody know if MK-0533 is aimed at thias?
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
